Luke Brunkhorst, DO
Urology · Iowa City, IANPI 1326200304
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,591 of the $5,827 with a category attached, or 78.8%. 26 manufacturers reported payments, led by Neotract Inc. at 30.1% of the total. Reporting peaked in 2019 at $2,349 and has fallen 90.4% since, to $225 in 2025.
Across 187 payments — averaging $31.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$2K
- Teleflex LLC$843
- Pfizer$638
- 180 Medical, Inc.$428
- Astellas Pharma US Inc$321
- Axonics, Inc.$266
- plus $2K from 20 others
What the payments were for
- Travel & lodging$1,04418%
- Food & beverage$4,59179%
- Education$1913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 18 | $1,752 |
| Teleflex LLC | 13 | $843 |
| Pfizer | 58 | $638 |
| 180 Medical, Inc. | 12 | $428 |
| Astellas Pharma US Inc | 12 | $321 |
| Axonics, Inc. | 8 | $266 |
| Johnson & Johnson | 17 | $241 |
| Coloplast | 6 | $188 |
| Bayer | 9 | $164 |
| Antares Pharma, Inc. | 9 | $154 |
| Prism Medical | 1 | $150 |
| Boston Scientific | 1 | $103 |
| Laborie Medical Technologies Corp. | 2 | $83 |
| Myriad Genetic Laboratories, Inc. | 1 | $68 |
| Calyxo, Inc. | 1 | $67 |
| AbbVie(2 entities) | 3 | $58 |
| Ferring Pharmaceuticals Inc. | 2 | $52 |
| Verity Pharmaceuticals Inc. | 3 | $49 |
| Merck | 2 | $43 |
| Valencia Technologies Corporation | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| AstraZeneca | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $13 |
| Urovant Sciences Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,353
- UroLift System$225
- Bulkamid$149
- UroLift 2 System$133
- AMS$103
- TITAN$101
How this compares
$5,827 in reported general payments places this provider in the 75th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 12 | $150,996 |
| MyrbetriqMirabegron | 29 | $19,183 |
| Trimethoprim | 95 | $8,067 |
| Tamsulosin Hcl | 239 | $4,216 |
| Testosterone | 11 | $2,374 |
| Potassium Citrate ErPotassium Citrate | 27 | $2,199 |
| Finasteride | 188 | $2,062 |
| Oxybutynin Chloride ErOxybutynin Chloride | 64 | $1,926 |
| Cephalexin | 62 | $1,096 |
| Ciprofloxacin Hcl | 62 | $684 |
| Testosterone Cypionate | 26 | $662 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $308 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $198 |
| Doxazosin Mesylate | 11 | $165 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $321 | $170,17941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 114 urology providers in Iowa.
Other urology in Iowa City
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
- Alexandria HertzIowa City$53K
- John BuieIowa City$52K
- Charles SchlaepferIowa City$51K
- Christopher CooperIowa City$10K
- Amanda MyersIowa City$7K
- Grant HenningIowa City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.